Welcome to our dedicated page for Macrogenics SEC filings (Ticker: MGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech reports can feel like a second language—especially when MacroGenics’ 10-K stretches across hundreds of pages of antibody platform science, trial data, and partnership milestones. If you have ever searched Google for “MacroGenics SEC filings explained simply” or wondered where to track “MacroGenics insider trading Form 4 transactions,” you know the challenge.
Stock Titan solves that problem. Our AI instantly translates every new document—whether it’s a “MacroGenics quarterly earnings report 10-Q filing,” an 8-K on fresh trial results, or a detailed proxy statement on executive compensation—into plain-English summaries with key numbers highlighted. Real-time alerts surface “MacroGenics Form 4 insider transactions” the moment executives buy or sell shares, while side-by-side visuals compare R&D spend trends across quarters. No more combing through dense exhibits to find collaboration revenue or cash-runway disclosures.
Inside this page you’ll find comprehensive coverage of every submission to EDGAR, including:
- 10-K / Annual Report: Cash burn, pipeline status, and “MacroGenics annual report 10-K simplified” sections for instant context.
- 10-Q / Earnings: “MacroGenics earnings report filing analysis” that links trial costs to balance-sheet strength.
- 8-K Material Events: “MacroGenics 8-K material events explained,” from FDA designations to partnership amendments.
- Form 4: “MacroGenics executive stock transactions Form 4” with real-time AI tagging.
- DEF 14A Proxy: Clear breakdowns of “MacroGenics proxy statement executive compensation.”
Whether you’re monitoring catalyst dates or simply understanding MacroGenics SEC documents with AI, Stock Titan delivers the insights professionals rely on—faster, clearer, and always up to date.
On 07/07/2025, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, filed a Schedule 13G revealing a 9,929,963-share position in MacroGenics, Inc. (MGNX) as of 06/01/2025. The stake equals 15.7 % of the company’s outstanding common stock. Both entities are incorporated in Switzerland and report shared voting and dispositive power over the entire holding, with zero sole voting or dispositive authority. Bellevue is classified as a “HC, CO” (parent holding company/control person) and Bellevue Asset Management AG as “CO.”
The certification states that the shares were acquired and are held in the ordinary course of business and are not intended to influence control of MacroGenics. This filing increases transparency around MacroGenics’ ownership structure and highlights a sizeable passive investment from a regulated Swiss financial institution.
FAQ
What is the current stock price of Macrogenics (MGNX)?
What is the market cap of Macrogenics (MGNX)?
What is the primary focus of Macrogenics Inc?
What distinguishes Macrogenics' product pipeline?
How does Macrogenics generate revenue?
What technological platforms support Macrogenics' research?
How does Macrogenics collaborate within the pharmaceutical industry?
Where does Macrogenics stand in the competitive biopharmaceutical landscape?
